Beyond Weight Loss:
The Full Potential of GLP-1 &
GIP Medications in Primary Care
Wednesday, April 2, 2025 at 7 PM (EST)
About The Webinar
The landscape of GLP-1 and GIP-based weight loss medications is rapidly evolving, and primary care physicians play a critical role in helping patients navigate their options. As interest in these medications grows, providers need up-to-date, evidence-based guidance on prescribing, managing side effects, addressing patient concerns, and optimizing outcomes.
Join QHSLab for an exclusive webinar featuring Reza Yavari, M.D., a Yale-trained, board-certified endocrinologist and one of New England’s leading prescribers of GLP-1 medications. Dr. Yavari will share practical insights from over a decade of experience using these medications to successfully treat patients with obesity, metabolic syndrome, and Type 2 diabetes.
Special Guest Speaker, Reza Yavari, MD
Reza Yavari, M.D. is a Yale-trained Board-Certified Endocrinologist with over 25 years of medical practice focused on diabetes, obesity, and therapeutic lifestyle change. He is the author of several books and many articles and has been active in teaching and lecturing to a variety of audiences nationwide. He is the author and designer of Beyond Weight®, a digital behavior modification application for lifestyle change aimed at diabetes and obesity, which won him the prestigious MIT – SOLVE innovation award. Dr. Yavari is the co-founder and medical advisor of several healthcare companies and is an Advisory Board member at QHSLab. His understanding of biomedical sciences and his experience in clinical medicine, as well as in digital health and machine learning, make him uniquely positioned as an innovator in patient-centric, data-driven healthcare.
Reza Yavari, MD
Board-Certified Endocrinologist, Author and Designer of Beyond Weight®, and Advisory Board Member of QHSLab, Inc.
Marcos A. Sanchez-Gonzalez, MD, PhD
VP of Medical and Scientific Affairs of QHSLab, Inc., Adjunct Professor of Health Services Administration and AI in Healthcare
Troy Grogan
President and CEO, QHSLab, Inc.
IN THIS SESSION, YOU WILL HAVE THE OPPORTUNITY TO:
- Understand the Prevalence and Impact of Obesity: Review obesity trends from 2014 to 2022 and their implications for patient health. Discuss the role of incretin-based therapies in addressing metabolic disorders.
- Examine the Evolution of Incretin-Based Therapies: Outline over 40 years of research on GLP-1 and GIP receptor agonists. Explore the mechanism of action of GLP-1/GIP drugs and their effects on weight loss and metabolic health.
- Compare Current and Emerging GLP-1/GIP Therapies: Differentiate among available and investigational GLP-1/GIP receptor agonists, including Tirzepatide, Semaglutide, and newer candidates in clinical trials. Assess the potential advantages and limitations of various drugs in development from companies such as Lilly, Novo Nordisk, and Novartis.
- Analyze Recent Clinical Data and Real-World Evidence: Interpret key findings from the JAMA Internal Medicine study comparing Tirzepatide and Semaglutide across 40,000 patients. Discuss EpicResearch outcomes on weight maintenance, including weight regain trends post-treatment.
- Apply Evidence-Based Guidelines in Clinical Practice: Identify patient populations who would benefit most from GLP-1/GIP therapies. Integrate treatment strategies that align with the latest clinical guidelines and research findings.
DON'T MISS YOUR CHANCE TO JOIN US! RSVP BELOW.
© QHSLab, Inc. | Legal Information